SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report March 26, 1997
CHEUNG LABORATORIES, INC.
MARYLAND
2-93826-W 52-1256615
(Commission File Number) (IRS Employer Identification Number)
10220 Old Columbia Road Suite I Columbia, MD 21046 Phone: (410) 290-5390
<PAGE>
March 26, 1997
Securities & Exchange Commission
Corporate Finance Division
Chief Counsel's Office
450 Fifth Street, N.W.
Washington, DC 20549-1007
RE: Cheung Laboratories, Inc.
SEC File No. 2-93826-W
Please find the attached report on Form 8-K for Cheung Laboratories, Inc.
Should you have any questions, please give us a call.
Very truly yours,
\s\ Verle D. Blaha
Verle D. Blaha
President
<PAGE>
ITEM 5: OTHER EVENTS 8K Filing
Cheung Laboratories, Inc. (the "Registrant') has completed its Microwave
Prostatic Treatment System as part of its exclusive license agreement for
the commercialization of an innovative patented technology to be used for
the treatment of symptomatic problems associated with prostatic diseases.
The Registrant, has shipped the completed system to the Montefiore/Albert
Einstein College of Medicine, in New York City to evaluate the technology
in an animal research agreement. Dr. Arnold Melman, Chairman and Professor,
Department of Urology at Montefiore/Albert Einstein College of Medicine will
be the Principle Investigator.
The Registrant believes the use of this technology is a viable treatment
alternative to drugs and surgery for the millions of men who suffer from
problems associated with enlarged prostates. The prostate is a walnut-sized
gland which surrounds the urethra just below the bladder. Benign Prostatic
Hyperplasia (BPH) is a common condition afflicting more than 50% of all men
over the age of 55.
This patented technology is a bi-modal approach which combines heat with
compression of the walls of the prostatic urethra to achieve better treatment
results. The Registrant believes this will give our BPH systems a
competitive advantage over existing systems. This bi-modal treatment can
be administered on an out-patient basis. The Registrant further believes
this patented technology has the potential to shorten the treatment time and
lower the treatment temperature, thus resulting in a safer and more patient-
friendly BPH treatment. Preclinical evaluation results using this new
technology are very encouraging. Before marketing and sales of this
technology is allowed in the USA, The Registrant must gain approval by the
Food and Drug Administration (FDA) with sufficient safety and efficacy data.
After the animal studies are completed, the Registrant plans to perform
clinical trials to get FDA approval..
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned thereunto duly authorized.
CHEUNG LABORATORIES, INC.
Date: March 26, 1997 By: \s\ Verle D. Blaha
Verle D. Blaha
President
